drowsiness. Modvigil from Hab Pharma is the most common and in demand pill for patients who are suffering from sleep apnea and other sleeping disorders. However‚ this is contraindicated if you have recent history of heart problems. If you are allergic to any constituents like Modafinil‚ it can lead to hypersensitivity reactions too. This is used for the treatment of narcolepsy and as a study aid because of its ability to focus and stay awake. It is said that Modafinil from Hab Pharma has low reports of side
Premium Sleep deprivation Sleep Patient
| |Key people |Samson H. Chowdhury[1] | |Website |http://www.squarepharma.com.bd/ | Corporate history of Square Pharma The company was founded in 1958 by Samson H. Chowdhury along with three of his friends as a private firm. It went public in 1991 and is currently listed on the Dhaka Stock Exchange. Square Pharmaceuticals Ltd.‚ the flagship company‚ is holding
Premium Corporation
Celine-Alisha Wolff Assessment One: The Kingdom of Armorika GDP Per capita Gross Domestic Product per capita enables comparison of countries on an individual level. Using the total production output of the country and dividing it among its population. This allows a measurement of how wealthy a country is compared to how many people there live. The Kingdom’s GDP per capita is US$48‚010. Armorika GDP ranks between Germany with a GDP per capita of US$46‚268 and Canada with a GDP per capita of US$51
Premium Gini coefficient Gross domestic product Lorenz curve
years. New large aircraft Throughout the history of aviation‚ aircraft manufacturers have provided air carriers with aircraft of ever-increasing size‚ payload capabilities‚ and range. The latest such effort is the A-380‚ being produced by Airbus Industrie. This "superjumbo" aircraft has specifications in length‚ wingspan‚ weight‚ and passenger- and cargo-carrying capabilities significantly greater than that of the next-largest aircraft in common existence‚ the Boeing 747. Because of its sheer size
Premium Airport Airline
Press. “US Regulators Approve 2nd Gene Therapy for Blood Cancer.” New York Times. October 18th. The Food and Drug Administration(FDA) approved a second gene therapy for a for a type of blood cancer and allowed the sales of the treatment from Kite Pharma. The therapy uses the same technology as the first gene therapy that the FDA approved in the U.S. in August. The treatment‚ called Yescaarta‚ is estimated to cost $373‚000 per patient. The technology‚ CAR-T‚ doesn’t fix the diseases-causing genes
Premium Cancer Oncology Chemotherapy
References: Book: Henderson‚ I 2012‚ Compensation Management in a Knowledge Based World‚ 10th edition‚ Dorling Kindersley‚ India. Websites: Beximco Pharma‚2012‚ Annual Report Beximco Pharma‚ Beximco Pharma‚viewed 16th December 2012‚<www.beximco-pharma.com › Investor Relations › Financial Reports>. Scribd‚2012‚Human Resource Practice in BEXIMCO-Pharmaceuticals Ltd.‚ scribd‚ viewed 22nd November 2012‚<http://www.scribd
Premium Medicine Employment compensation Employment
31 V. Competitor Analysis 31 VI. Ranbaxy Financials 32 VII. Pharmaceutical Industry Future 33 VIII. Conservation of energy and its impact 37 Executive Summary Product patent regime implemented in India from Jan 2005 compelled Indian pharma companies to relook in to their marketing strategies so as to become competitive & strongly withstand in the competition with MNC’s & big giants in domestic markets. Product patent regime posed Indian pharmaceutical companies to change their
Premium Generic drug Pharmaceutical industry Ranbaxy Laboratories
Table of Contents 1.0 Introduction 2 1.1 Objectives 2 1.2 Overview of the Organization 2 2.0 Market Share and Competition in the industry 3 2.1 Market Share 3 2.2 Portfolio 4 2.3 Competition 5 3.0 Industry Market Structure 7 4.0 Conclusion 8 5.0 References 9 1.0 Introduction 1.1 Objectives This assignment was prepared to understand and present an overview of GlaxoSmithKline (GSK)‚ in the pharmaceutical industry and its competition against its distributors in Sri Lanka and also
Premium Pharmaceutical industry
Chairmen‚ recognized that the company had grown as far as it could within its home market. He hired Dr. Joseph Aleksandrowicz to head the strategic planning process for the company. Still‚ Teva focused on generic or “bioequivalent” versions of the Big Pharma or what they call the their innovative counterparts. These innovative companies‚ who had more capital and controlled a lot of the industry‚ were going to pose a big threat to Teva. Not only were they fighting patent challenges against the small generics
Premium Pharmaceutical industry Generic drug
com/profile/preview?locale=en_US&tr... % $ Dr. Gregg Clopath 1st Biotechnology Current CEO at andZyme Bioscience (USA)‚ CEO at andZyme Bioscience (Middle East and Africa)‚ CEO at andZyme Bioscience (Spain) Previous Max Zeller Soehne AG‚ Merz Pharma‚ Nestle Education Université de Lausanne 297 Send a message connections ! 2 4 ’ 8 ( Ads You May Be Interested In หลักสูตร MBA USC Marshall เตรียมพร้อมเป็นผู้บริหารระดับสูง เรียน 1ปี L.A. หรือ Part-time ที่ Shanghai CEO at andZyme Bioscience
Premium Management Biotechnology Business development